Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

Modern drug development approaches that integrate functional plans with larger business goals are needed for success in early ...

It would help the trials—and patients—if more people were tested for Alzheimer’s earlier on, so that they could be enrolled ...

What are some of the most exciting drugs in the dementia drug discovery pipeline right now? How has Alzheimer’s drug development changed over the years? Beyond the anti-amyloid drugs, what other types ...

This guide provides an overview of quantitation solutions that provide the sensitivity, robustness and compliance-ready ...

One clinical trial is assessing whether semaglutide, used in weight loss drugs, could slow the progression of dementia ...

Experts say more than 100 potential dementia drugs could one day be used to "slow and ultimately stop" Alzheimer's disease ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

There are more than a hundred different drugs are in clinical trials for treating or preventing Alzheimer's disease ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

The National Institute for Health and Care Excellence is taking more evidence and is expected to announce its decision in the ...